Andre Bouhasin, MD
Interventional Cardiology · Farmington, MONPI 1508808635
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Philips North America LLC at 49.1% of the total. Reporting peaked in 2022 at $37,010 and has fallen 79.1% since, to $7,727 in 2025.
Across 1,033 payments — averaging $68.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$35K
- GE HealthCare$13K
- Boston Scientific$6K
- Johnson & Johnson$2K
- Amgen$2K
- Biotronik Inc.$2K
- plus $11K from 41 others
What the payments were for
- Consulting fees$40,65358%
- Speaking & faculty fees$5,7678%
- Travel & lodging$4,0116%
- Food & beverage$20,03728%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (9520) IGT Devices Undivided$34,000
- OEC$7,506
- Watchman$2,286
- WATCHMAN Access System$1,331
- AMVIA EDGE$278
- Acticor 7 VR-T DX$259
- BioMonitor$254
- (6554) Periph Vasc Undiv$225
- ARTIX MT$152
- BioMimics$135
- GENERAL VASCULAR INTERVENTION$129
- Rivacor$124
- Solia$124
- Edora$124
- Acticor$124
- FARXIGA$124
- Indigo$123
- ORENITRAM$121
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$119
- GENERAL METALLIC STENTS$115
How this compares
$70,553 in reported general payments places this provider in the 85th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 769 | $678,079 |
| XareltoRivaroxaban | 421 | $351,904 |
| OpsumitMacitentan | 18 | $227,549 |
| EntrestoSacubitril/Valsartan | 131 | $141,016 |
| OzempicSemaglutide | 84 | $110,915 |
| Repatha SureclickEvolocumab | 145 | $99,797 |
| CamzyosMavacamten | 11 | $93,265 |
| JardianceEmpagliflozin | 92 | $91,636 |
| FarxigaDapagliflozin Propanediol | 82 | $90,079 |
| MounjaroTirzepatide | 26 | $31,661 |
| Tadalafil | 26 | $30,161 |
| Repatha SyringeEvolocumab | 35 | $28,914 |
| MultaqDronedarone Hcl | 29 | $27,798 |
| WegovySemaglutide | 17 | $26,522 |
| Praluent PenAlirocumab | 39 | $23,130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $227 | $678,079769 claims |
| Johnson & JohnsonXarelto | $2,237 | $351,904421 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,091 | $227,54918 claims |
| NovartisEntresto | $1,385 | $141,016131 claims |
| Novo NordiskOzempic, Wegovy | $155 | $137,437101 claims |
| AstraZenecaFarxiga, Brilinta | $1,123 | $98,95798 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $1,273 | $93,26511 claims |
| Boehringer IngelheimJardiance | $736 | $91,63692 claims |
| Lilly USA, LLCMounjaro | $21 | $31,66126 claims |
| Sanofi-aventis U.S. LLCMultaq | $205 | $27,79829 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $260 | $22,28236 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $55 | $3,46112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Farmington
- Azamuddin KhajaFarmington$21K
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Gerald MancusoKansas City$402K
- James GranthamKansas City$357K
- Matthew BunteKansas City$242K
- Alan ZajariasSaint Louis$203K
- Anish ThomasSaint Louis$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.